Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab

Next Previous
Trial Profile

MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daratumumab (Primary) ; Durvalumab (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms FUSION-MM-005
  • Sponsors Celgene Corporation

Most Recent Events

  • 22 Jul 2019 Results assessing a population-PK model of durvalumab using pooled data from four clinical trials of haematologic malignancies (NCT02775903, NCT02685826, NCT03000452, NCT02733042) and the model structure and covariate effects were compared with those in solid tumours published in the Clinical Pharmacokinetics
  • 18 Sep 2018 Status changed to completed.
  • 29 Jan 2018 Status changed from suspended to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top